24.5 C
Washington

Lilly to build $2.5 billion Germany plant as obesity drug demand soars | Reuters News Agency

Date:

Share:

DealsHealth

Reuters exclusively reported that Eli Lilly (LLY.N) will build its first plant in Germany in the western town of Alzey for 2.3 billion euros ($2.5 billion), the U.S. drugmaker said on Friday, as the sector scrambles to meet soaring demand for new diabetes and obesity therapies. 

Market Impact

As the sector scrambles to meet demand for new diabetes and obesity therapies, the investment, confirmed by Lilly on Nov 17, will contribute to meeting surging demand for weight-loss drug Mounjaro from 2027. Eli Lilly and Danish rival Novo Nordisk (NOVOb.CO) are leading a race to seize an estimated $100 billion future global market for anti-obesity treatments.   

Article Tags

Topics of Interest: DealsHealth

Type: Reuters Best

Sectors: Pharmaceuticals & HealthcareRetail & Consumer Goods

Regions: Europe

Countries: Germany

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Important Regional Story

Source link

Subscribe to our magazine

━ more like this

Video: The Volunteer Groups Preparing for a Post-FEMA World

As the Trump administration threatens to dismantle FEMA, military veterans and other volunteers are preparing to take a bigger role in disaster relief. Emily...

Weight loss jabs study begins after reports of pancreas issues

Getty ImagesA study into potential serious side effects of weight loss jabs has been launched after hundreds of people reported problems with their pancreas....

Access Denied

Access Denied You don't have permission to access "http://www.ndtv.com/business-news/sensex-nifty-jump-in-early-trade-as-tensions-ease-in-middle-east-8755060" on this server. Reference #18.1c0c2d17.1750980844.20843c77 https://errors.edgesuite.net/18.1c0c2d17.1750980844.20843c77 Source link